Exploring glucagon-like peptide-1 receptor agonists as potential disease-modifying agent in psychiatric and neurodevelopmental conditions: evidence from a drug target Mendelian randomization

Abstract Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have recently received Food and Drug Administration (FDA) approval for obesity management. However, the causal relationship between GLP-1RAs and psychiatric and neurodevelopmental conditions remains unclear. Methods We used Men...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Lingfeng Zhang, Xiang Chen, Yantao Xu, Jiachen Liu, Zhongchun Liu
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	BMC 2025-05-01
Ráidu:	BMC Psychiatry
Fáttát:	GLP-1R agonists Psychiatric and neurodevelopmental conditions Drug target Mendelian randomization
Liŋkkat:	https://doi.org/10.1186/s12888-025-06914-0
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!